Edition:
United States

Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

2,648.10INR
23 Jun 2017
Change (% chg)

Rs18.65 (+0.71%)
Prev Close
Rs2,629.45
Open
Rs2,635.15
Day's High
Rs2,659.10
Day's Low
Rs2,618.00
Volume
20,843
Avg. Vol
41,765
52-wk High
Rs3,689.00
52-wk Low
Rs2,382.05

Latest Key Developments (Source: Significant Developments)

Dr.Reddy's Labs gets form 483 with 3 observations from USFDA for audit of Miryalaguda plant
Tuesday, 21 Feb 2017 08:10am EST 

Dr.Reddy's Laboratories Ltd : Says the audit of API manufacturing plant at Miryalaguda, by the US FDA, has been completed on February 21, 2017 .Co has been issued a form 483 with three observations.  Full Article

Dr.Reddy's Labs says co not served with legal papers in matter as in Mezzion's press release
Friday, 27 Jan 2017 04:57am EST 

Dr.Reddy's Laboratories Ltd : Dr.Reddy's Laboratories clarifies on news item "Korean biotech firm Mezzion Pharma files suit against Dr Reddy's laboratories." .Dr.Reddy's Laboratories Ltd says co not been served with legal papers or process in matter as in Mezzion's press release.  Full Article

Dr. Reddy's Labs says U.S. FDA re-audit of co's plants part of "usual activity"
Thursday, 12 Jan 2017 03:13am EST 

Dr.Reddy's Laboratories Ltd : Clarifies on news item "FDA to re-audit three Dr.Reddy's labs plants" .Says believes that schedule of audit by USFDA is usual activity.  Full Article

Sucampo Q3 adjusted EPS $0.28
Wednesday, 9 Nov 2016 06:30am EST 

Sucampo Pharmaceuticals Inc : Sucampo pharmaceuticals inc - company raises 2016 guidance and provides preliminary 2017 guidance . Sucampo pharmaceuticals inc - announces settlement with dr. Reddy's laboratories for amitiza . Sees 2016 total revenue $220.0 million to $225.0 million . Fy2016 earnings per share view $1.03, revenue view $205.7 million -- Thomson Reuters I/B/E/S . Sees 2016 adjusted ebitda $110.0 million to $115.0 million . Sucampo pharmaceuticals - phase 3 trial of amitiza in pediatric functional constipation in children 6-17 yrs of age did not achieve primary endpoint . Sucampo pharmaceuticals inc- completed a settlement and license agreement with dr. Reddy's laboratories, ltd. And certain of its affiliates . Sucampo pharmaceuticals - agreement resolves patent litigation in united states related to sucampo's amitiza 8 mcg and 24 mcg soft gelatin capsules . Sucampo pharmaceuticals - agreement provides for an entry date more than six years from wednesday and profit sharing on product sales by dr. Reddy's . Sucampo reports third quarter 2016 financial results . Q3 adjusted earnings per share $0.28 . Q3 gaap earnings per share $0.19 . Q3 revenue $57.9 million versus i/b/e/s view $51.4 million . Q3 earnings per share view $0.27 -- Thomson Reuters I/B/E/S .Sees fy 2016 adjusted earnings per share $1.20 to $1.25.  Full Article

Dr.Reddy's Labs exec says co has addressed all FDA requirements on warning letters
Tuesday, 25 Oct 2016 09:33am EDT 

Dr.Reddy's Laboratories Ltd : Exec says have addressed all FDA requirements on warning letters . Exec says pricing erosion has become a part of U.S. business model Further company coverage: [REDY.NS] (Bengaluru newsroom) ((ReutersIndia.snapping@thomsonreuters.com ;)).  Full Article

Dr.Reddy's Labs announces entry into Columbia
Friday, 7 Oct 2016 09:11am EDT 

Dr.Reddy's Laboratories Ltd :Announces entry into Columbia.  Full Article

DR. Reddy's laboratories says launch of Bupropion HCL extended-release tablets, USP (sr) in U.S. market
Friday, 2 Sep 2016 11:32am EDT 

Dr.Reddy's Laboratories Ltd :Launch of bupropion hcl extended-release tablets, usp (sr) in u.s. Market.  Full Article

Dr.Reddy's Laboratories says June-qtr consol net profit falls about 76.2 pct
Tuesday, 26 Jul 2016 05:12am EDT 

Dr.Reddy's Laboratories Ltd : June -quarter pat 4.09 billion rupees - tv . June -quarter consol net profit 1.54 billion rupees; consol net sales inr 31.64 billion . Consensus forecast for June-quarter profit was 4.95 billion rupees . Consol net profit in June-quarter last year was 6.47 billion rupees as per Ind-AS; consol net sales was 37.01 billion rupees . In quarter, top and bottom lines impacted by fall in volume growth, mainly in U.S. markets, loss of business in Venezuela . Co faced challenges in quarter including price erosion and delayed launches due to warning letter, which significantly impacted earnings .  Full Article

Spectrum Pharma says Dr Reddy's will be permitted to market generic version of Folotyn in US on Dec 1, 2022 or earlier
Tuesday, 31 May 2016 07:02am EDT 

Spectrum Pharmaceuticals : Co's unit, dr. Reddy's labs, ltd entered into settlement agreement to resolve their patent litigation relating to folotyn .dr. Reddy's will be permitted to market generic version of folotyn in u.s. On december 1, 2022 or earlier under certain circumstances.  Full Article

Dr. Reddy's Labs acquires six OTC brands from Ducere Pharma
Wednesday, 25 May 2016 05:27am EDT 

Dr.Reddy's Laboratories Ltd : Dr. Reddy's enters the branded consumer health arena through the acquisition of six OTC brands . Co acquired six OTC brands from Ducere Pharma .  Full Article

More From Around the Web

BRIEF-Dr. Reddy's Lab says USFDA issues form 483 with one observation for Srikakulam Plant

* Says formulations Srikakulam Plant (SEZ) unit I, Andhra Pradesh, by US FDA, has been completed Friday